Cancer immunotherapy, which harnesses the power of the immune system to fight cancer, has revolutionized cancer treatment over the last decade. However, many patients experience resistance to these therapies, leading to treatment failure and relapse. To address this pressing issue, we are issuing a call for scientific articles on the subject of "Overcoming Cancer Immunotherapy Resistance".
The importance of this topic cannot be overstated. Despite the success of cancer immunotherapies, many patients experience primary, adaptive, or acquired resistance to these treatments. Understanding and overcoming resistance mechanisms is crucial to improve the effectiveness of cancer immunotherapy and broaden the population of patients benefiting from these therapies.
We welcome submissions that address any aspect of cancer immunotherapy resistance, including but not limited to: mechanisms of resistance, biomarkers of resistance, combination therapies, and novel strategies for overcoming resistance. We are also interested in articles that discuss the clinical implications of resistance, including patient outcomes and quality of life. We welcome original research articles, reviews, and perspective articles.
Dr. Snook is a cancer immunologist in the Departments of Pharmacology, Physiology, & Cancer Biology and Microbiology & Immunology at Thomas Jefferson University where he is developing new cancer immunotherapies. His work has led to investigator-initiated clinical trials examining colorectal cancer chemoprevention, cancer vaccines, and CAR-T cell therapies. He is an Assistant Program Leader of the Immune Cell Regulation and Targeting (IRT) Program of the Sidney Kimmel Cancer Center. He is also Director of the Clinical & Translational Research track of the JeffMD Scholarly Inquiry Program of the Sidney Kimmel Medical College.
You can learn more about his work by visiting https://research.jefferson.edu/labs/researcher/snook-laboratory.html
